Pharmaceutical companies by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Edgewise Therapeutics has the lowest figure of the 33 pharmaceutical companies ranked by P/E ratio, at 4.9, followed by Alnylam Pharmaceuticals (7.5) and Novo Nordisk (10.0). Figures as of 18 Nov 2026, 22:14 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- Lowest
- Edgewise Therapeutics4.9
- Median
- 40.1
- Combined market value
- CZK 112.36T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/E ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | CZK 100.6B | CZK 918.83 | 1.59% down | 88% up | ||
| 2 | Alnylam PharmaceuticalsALNY · Health Care | 7.5 | CZK 444.4B | CZK 3,318.17 | 4.54% down | 66% down | ||
| 3 | Novo NordiskNVO · Health Care | 10.0 | CZK 3.86T | CZK 875.74 | 3.12% down | 17% down | ||
| 4 | GrifolsGRFS · Health Care | 10.2 | CZK 128B | CZK 188.12 | 1.85% down | 1% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | 13.2 | CZK 2.7T | CZK 1,322.83 | 2.92% down | 34% up | ||
| 6 | ZoetisZTS · Health Care | 14.6 | CZK 772.2B | CZK 1,900.51 | 2.50% up | 29% down | ||
| 7 | GSKGSK · Health Care | 16.9 | CZK 2.16T | CZK 1,078.96 | 1.34% down | 6% up | ||
| 8 | Ascendis PharmaASND · Health Care | 17.8 | CZK 393.8B | CZK 6,004.03 | 0.32% down | 28% up | ||
| 9 | Regeneron PharmaceuticalsREGN · Health Care | 20.9 | CZK 2.17T | CZK 21,000.22 | 1.28% down | 36% up | ||
| 10 | United TherapeuticsUTHR · Health Care | 21.8 | CZK 546.1B | CZK 12,822.72 | 1.16% down | 23% up | ||
| 11 | SanofiSNY · Health Care | 23.4 | CZK 2.51T | CZK 1,046.54 | 0.86% down | 4% down | ||
| 12 | AstraZenecaAZN · Health Care | 25.3 | CZK 6.16T | CZK 3,970.26 | 1.93% down | 2% up | ||
| 13 | Protagonist TherapeuticsPTGX · Health Care | 26.9 | CZK 184.3B | CZK 2,824.22 | 2.00% up | 46% up | ||
| 14 | NovartisNVS · Health Care | 29.6 | CZK 6.51T | CZK 3,447.21 | 2.46% down | 25% up | ||
| 15 | Vertex PharmaceuticalsVRTX · Health Care | 34.5 | CZK 3.02T | CZK 11,914.55 | 0.42% up | 27% up | ||
| 16 | Abbott LaboratoriesABT · Health Care | 39.0 | CZK 4.02T | CZK 2,320.50 | 0.22% down | 17% down | ||
| 17 | PfizerPFE · Health Care | 40.1 | CZK 3.55T | CZK 623.21 | 1.44% down | 14% up | ||
| 18 | Johnson & JohnsonJNJ · Health Care | 41.4 | CZK 14.58T | CZK 6,056.67 | 2.15% down | 38% up | ||
| 19 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.6 | CZK 277.4B | CZK 332.71 | 1.28% up | 5% up | ||
| 20 | GenmabGMAB · Health Care | 43.6 | CZK 698B | CZK 1,132.04 | 1.91% down | 70% up | ||
| 21 | Eli LillyLLY · Health Care | 44.9 | CZK 27.36T | CZK 30,710.88 | 2.32% down | 35% up | ||
| 22 | Royalty PharmaRPRX · Health Care | 44.9 | CZK 877B | CZK 1,525.16 | 0.01% down | 78% up | ||
| 23 | AbbVieABBV · Health Care | 49.1 | CZK 11.23T | CZK 6,352.28 | 2.33% down | 26% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | 51.0 | CZK 164.8B | CZK 1,505.62 | 3.25% down | 8% down | ||
| 25 | BeOne MedicinesONC · Health Care | 51.7 | CZK 1.02T | CZK 8,963.96 | 2.34% down | 17% up | ||
| 26 | Amneal PharmaceuticalsAMRX · Health Care | 54.7 | CZK 169.3B | CZK 485.95 | 3.60% up | 83% up | ||
| 27 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 72.0 | CZK 165.9B | CZK 2,111.06 | 0.06% down | 126% up | ||
| 28 | Jazz PharmaceuticalsJAZZ · Health Care | 73.3 | CZK 353.2B | CZK 5,502.97 | 2.93% up | 37% up | ||
| 29 | Teva Pharmaceutical IndustriesTEVA · Health Care | 98.2 | CZK 1.09T | CZK 937.93 | 0.92% down | 74% up | ||
| 30 | TG TherapeuticsTGTX · Health Care | 98.7 | CZK 222B | CZK 1,468.53 | 5.44% up | 107% up | ||
| 31 | Ligand PharmaceuticalsLGND · Health Care | 120 | CZK 132.7B | CZK 6,634.35 | 1.67% up | 43% up | ||
| 32 | Merck & CoMRK · Health Care | 139 | CZK 7.54T | CZK 3,060.09 | 3.90% down | 51% up | ||
| 33 | Takeda PharmaceuticalTAK · Health Care | 304 | CZK 1.51T | CZK 472.41 | 1.71% down | 54% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 22.2100 CZK). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies have the lowest P/E ratio?
Edgewise Therapeutics (4.9), Alnylam Pharmaceuticals (7.5) and Novo Nordisk (10.0) have the lowest P/E ratio of the 33 pharmaceutical companies ranked here as of 18 Nov 2026, 22:14 UTC.
How many pharmaceutical companies are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 33 pharmaceutical companies ranked by P/E ratio have a combined market value of CZK 112.36T as of 18 Nov 2026, 22:14 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/E ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.